Zacks.com on MSN10h
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to KnowIn the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD ...
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...
The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...
The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth r ...
When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
Heading into the end of the year, the investment market has given us and our clients plenty to be thankful for Even so, more ...
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.
Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback